This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/ontology/domain/vavai/
n9http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n5http://bibframe.org/vocab/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F14%3A10284184%21RIV15-MSM-11110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F14%3A10284184%21RIV15-MSM-11110___
rdf:type
n16:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1016/j.pnpbp.2013.12.001
dcterms:description
Background: Glycogen synthase kinase-3 beta (GSK3 beta), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). Methods: This study was designed to determine the association of GSK3 beta activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3 beta activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assessed for severity of depression. Results: We observed increased CREB activity and GSK3 beta activity in AD with depressive symptoms or in AD at mild stage of dementia. Decreased BDNF concentration was found in platelet-rich plasma of AD patients at moderate to severe stages of dementia or in AD without depressive symptoms. An association was revealed of the severity of cognitive impairment with the increase of GSK3 beta in the platelets of AD patients with mild dementia. In depressive patients, a lower concentration of phosphorylated GSK3 beta was associated with a higher severity of depression. Association was confirmed between severity of depression, CREB activation, and BDNF concentration in drug-naive depressive patients. Conclusion: Our data demonstrated that AD is accompanied by increased CREB activity in lymphocytes and a decreased concentration of BDNF in platelet-rich plasma. The decreased BDNF concentration appears to correlate with moderate to severe stages of dementia in AD. Background: Glycogen synthase kinase-3 beta (GSK3 beta), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). Methods: This study was designed to determine the association of GSK3 beta activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3 beta activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assessed for severity of depression. Results: We observed increased CREB activity and GSK3 beta activity in AD with depressive symptoms or in AD at mild stage of dementia. Decreased BDNF concentration was found in platelet-rich plasma of AD patients at moderate to severe stages of dementia or in AD without depressive symptoms. An association was revealed of the severity of cognitive impairment with the increase of GSK3 beta in the platelets of AD patients with mild dementia. In depressive patients, a lower concentration of phosphorylated GSK3 beta was associated with a higher severity of depression. Association was confirmed between severity of depression, CREB activation, and BDNF concentration in drug-naive depressive patients. Conclusion: Our data demonstrated that AD is accompanied by increased CREB activity in lymphocytes and a decreased concentration of BDNF in platelet-rich plasma. The decreased BDNF concentration appears to correlate with moderate to severe stages of dementia in AD.
dcterms:title
GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression
skos:prefLabel
GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression
skos:notation
RIV/00216208:11110/14:10284184!RIV15-MSM-11110___
n3:aktivita
n6:I n6:Z
n3:aktivity
I, Z(MSM0021620849)
n3:cisloPeriodika
April
n3:dodaniDat
n11:2015
n3:domaciTvurceVysledku
n4:7722672 n4:9704132 n4:7337280 n4:8854505 n4:1603477 n4:6189431 n4:7303211
n3:druhVysledku
n20:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
18665
n3:idVysledku
RIV/00216208:11110/14:10284184
n3:jazykVysledku
n19:eng
n3:klicovaSlova
GSK3 beta; Depressive disorder; CREB; BDNF; Alzheimer's disease
n3:klicoveSlovo
n10:CREB n10:BDNF n10:Depressive%20disorder n10:Alzheimer%27s%20disease n10:GSK3%20beta
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[842141C566D6]
n3:nazevZdroje
Progress in Neuro-Psychopharmacology and Biological Psychiatry
n3:obor
n18:FL
n3:pocetDomacichTvurcuVysledku
7
n3:pocetTvurcuVysledku
7
n3:rokUplatneniVysledku
n11:2014
n3:svazekPeriodika
50
n3:tvurceVysledku
Raboch, Jiří Jirák, Roman Fišar, Zdeněk Pláteník, Jan Buchal, Richard Kitzlerová, Eva Zvěřová, Martina
n3:wos
000330574000010
n3:zamer
n9:MSM0021620849
s:issn
0278-5846
s:numberOfPages
11
n5:doi
10.1016/j.pnpbp.2013.12.001
n12:organizacniJednotka
11110